eFFECTOR Therapeutics, Inc.
EFTRDelisted Jul 19, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828522
eFFECTOR Therapeutics, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $251.1K in total; no superinvestor held it.
13F holders, Q3 2024
Institutional positions in eFFECTOR Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
EFTR is no longer listed, and 13F filings after Q2 2024 list far fewer holders. See Q2 2024
- Institutional holders
- 3
- −15 vs. Q2 2024
- Shares held
- 114.2K
- −753.8K (−86.8%) vs. Q2 2024
- Total value
- $4.33K
- −$246.8K (−98.3%) vs. Q2 2024
- New holders
- 0
- 0 more added
- Sold out
- 15
- 1 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EFTR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 1 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 3 | $4.33K |
| Q2 2024 | 18 | $251.1K |
| Q1 2024 | 17 | $13.5M |
| Q4 2023 | 24 | $5.44M |
| Q3 2023 | 29 | $14.0M |
| Q2 2023 | 33 | $20.2M |
| Q1 2023 | 26 | $8.29M |
| Q4 2022 | 30 | $10.4M |
| Q3 2022 | 27 | $13.7M |
| Q2 2022 | 24 | $33.9M |
| Q1 2022 | 19 | $89.7M |
| Q4 2021 | 18 | $174.2M |
| Q3 2021 | 12 | $187.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding eFFECTOR Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 61,758 | $2.29K | 0.03% | −290,326−82.5% | Reduced |
| Blackstone Group Inc. | 52,343 | $2.04K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 100 | $4 | 0.00% | 00.0% | Unchanged |
| Carlyle Group Inc. | 0 | $0 | 0.00% | −192,884−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −67,738−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −61,667−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −25,583−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −25,070−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −21,528−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −18,669−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −18,021−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −11,115−100.0% | Sold out |
| Sea Otter Advisors LLC | 0 | $0 | 0.00% | −10,557−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −9,805−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −240−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −31−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −546−100.0% | Sold out |